Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G. Cortellini A, et al. Among authors: baldessari c. Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May 30. Cancer Immunol Immunother. 2020. PMID: 32474768 Free PMC article.
Stevens-Johnson syndrome during nivolumab treatment of NSCLC.
Salati M, Pifferi M, Baldessari C, Bertolini F, Tomasello C, Cascinu S, Barbieri F. Salati M, et al. Among authors: baldessari c. Ann Oncol. 2018 Jan 1;29(1):283-284. doi: 10.1093/annonc/mdx640. Ann Oncol. 2018. PMID: 29045532 Free article. No abstract available.
Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
Depenni R, Cossu Rocca M, Ferrari D, Azzarello G, Baldessari C, Alù M, Nolé F, Codecà C, Boscolo G, Piccininni M, Cavalieri S, Bossi P. Depenni R, et al. Among authors: baldessari c. Eur J Cancer. 2019 Jul;115:4-12. doi: 10.1016/j.ejca.2019.03.022. Epub 2019 May 10. Eur J Cancer. 2019. PMID: 31082692
Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.
Vitale MG, Baldessari C, Milella M, Buti S, Militello AM, Di Girolamo S, Fornarini G, Perri G, Basso U, Maruzzo M, Porta C, Cosmai L, Pipitone S, Cerma K, Cascinu S, Sabbatini R. Vitale MG, et al. Among authors: baldessari c. Clin Genitourin Cancer. 2019 Oct;17(5):e903-e908. doi: 10.1016/j.clgc.2019.06.009. Epub 2019 Jul 8. Clin Genitourin Cancer. 2019. PMID: 31375351 Review. No abstract available.
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma.
Losi L, Bertolini F, Guaitoli G, Fabbiani L, Banchelli F, Ambrosini-Spaltro A, Botticelli L, Scurani L, Baldessari C, Barbieri F, Cascinu S, Maiorana A. Losi L, et al. Among authors: baldessari c. Int J Oncol. 2019 Nov;55(5):1157-1164. doi: 10.3892/ijo.2019.4883. Epub 2019 Sep 20. Int J Oncol. 2019. PMID: 31545419
Treating cancer with immunotherapy in HIV-positive patients: A challenging reality.
Guaitoli G, Baldessari C, Maur M, Mussini C, Meschiari M, Barbieri F, Cascinu S, Bertolini F. Guaitoli G, et al. Among authors: baldessari c. Crit Rev Oncol Hematol. 2020 Jan;145:102836. doi: 10.1016/j.critrevonc.2019.102836. Epub 2019 Nov 26. Crit Rev Oncol Hematol. 2020. PMID: 31918216 Review.
57 results